These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6957239)

  • 41. Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusion.
    Hande K; Gay J; Gober J; Greco FA
    Cancer Treat Rev; 1980 Sep; 7 Suppl 1():25-30. PubMed ID: 7438118
    [No Abstract]   [Full Text] [Related]  

  • 42. Biodegradation of the antineoplastics vindesine, vincristine, and vinblastine and their toxicity against bacteria in the aquatic environment.
    Al-Ahmad A; Kümmerer K
    Cancer Detect Prev; 2001; 25(1):102-7. PubMed ID: 11270417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Phase II study of the treatment of CML blast crisis with vindesine and prednisone].
    Jehn U; Mezger J
    Onkologie; 1984 Dec; 7(6):342-5. PubMed ID: 6396561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effects of vinca alkaloids (VCR, VDS) and epipodophyllotoxin (VP16) on murine myeloblastic leukaemia.
    Yamashita Y; Nara N; Murohashi I; Imai Y; Aoki N
    Br J Cancer; 1987 May; 55(5):517-9. PubMed ID: 3475108
    [No Abstract]   [Full Text] [Related]  

  • 45. Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells.
    Van Belle SJ; De Smet MC; De Mey JE; Storme GA
    Anticancer Res; 1991; 11(1):465-71. PubMed ID: 2018383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood.
    Krivit W; Chilcote R; Pyesmany A; Anderson J; Hammond D
    Cancer Chemother Pharmacol; 1979; 2(4):267-70. PubMed ID: 287570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stimulating capacity of blast cells from patients with chronic myelocytic leukaemia, in blastic crisis in 'one-way' mixed lymphoycte reaction: lack of evidence for T lymphoblastic conversion.
    Han T; Gomez GA; Minowada J
    Immunology; 1978 Aug; 35(2):299-305. PubMed ID: 155646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Establishment and properties of vincristine-resistant human myelogenous leukemia K562.
    Tsuruo T; Iida H; Ohkochi E; Tsukagoshi S; Sakurai Y
    Gan; 1983 Oct; 74(5):751-8. PubMed ID: 6580255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
    Dorr RT; Alberts DS
    J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A presumed transient hemolytic reaction following vinca alkaloids administration in patients with hematological malignancies].
    Iwata N; Wakamatsu E; Oike S; Umegae S; Omine M; Maekawa T; Tsuchiya J
    Rinsho Ketsueki; 1984 May; 25(5):649-54. PubMed ID: 6590896
    [No Abstract]   [Full Text] [Related]  

  • 52. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy.
    Kris MG; Pablo D; Gralla RJ; Burke MT; Prestifilippo J; Lewin D
    Cancer Treat Rep; 1984; 68(7-8):1029-31. PubMed ID: 6744336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic inhibitory effects of dipyridamole and vincristine on the growth of human leukaemia and lymphoma cell lines.
    Hirose M; Takeda E; Ninomiya T; Kuroda Y; Miyao M
    Br J Cancer; 1987 Oct; 56(4):413-7. PubMed ID: 3479994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vindesine in the treatment of refractory haematological malignant diseases.
    Young GA; Jurd J; Vincent PC
    Med J Aust; 1985 Feb; 142(3):189-90. PubMed ID: 3969034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II study of vindesine in patients with hematological malignancies.
    Hulhoven R; Michaux JL; Cornu G; Ferránt A; Bosly A; Delannoy A; Sokal G
    Biomedicine; 1980 Apr; 33(2):31-2. PubMed ID: 6931617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
    Jordan MA; Himes RH; Wilson L
    Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired vs innate multidrug resistance and the effect of calcium channel blockers.
    Tsuruo T
    Prog Clin Biol Res; 1986; 223():203-16. PubMed ID: 3468516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.
    Johnson JR; Ford CH; Newman CE; Woodhouse CS; Rowland GF; Simmonds RG
    Br J Cancer; 1981 Sep; 44(3):472-5. PubMed ID: 7284242
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial.
    Anderson J; Krivit W; Chilcote R; Pyesmany A; Chard R; Hammond D
    Cancer Treat Rep; 1981; 65(11-12):1015-9. PubMed ID: 6945911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of vinorelbine on human leukemia cells.
    Landini I; Bartolozzi B; Banchelli I; Degli Innocenti A; Nocentini O; Bernabei PA
    J Chemother; 2001 Jun; 13(3):309-15. PubMed ID: 11450890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.